Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions by Christopher J Lord, Niall Quinn, Colm J Ryan

Get full text

Resistance to DNA repair inhibitors in cancer by Joseph S. Baxter, Diana Zatreanu, Stephen J. Pettitt, Christopher J. Lord

Get full text

Beyond DNA repair: the novel immunological potential of PARP inhibitors by Roman M. Chabanon, Jean-Charles Soria, Christopher J. Lord, Sophie Postel-Vinay

Get full text

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer by Agnieszka K. Witkiewicz, Sejin Chung, Rachel Brough, Paris Vail, Jorge Franco, Christopher J. Lord, Erik S. Knudsen

Get full text

Opinion: PARP inhibitors in cancer—what do we still need to know? by Andrew J. Wicks, Dragomir B. Krastev, Stephen J. Pettitt, Andrew N. J. Tutt, Christopher J. Lord

Get full text

Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells by Ilirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, Rachel Brough, Jessica Frankum, Christopher J. Lord, Alan Ashworth

Get full text

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth

Get full text

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth

Get full text

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. by Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth

Get full text

Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. by Louise J Barber, Juan M Rosa Rosa, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Costas Mitsopoulos, David Sims, Jarle Hakas, Marketa Zvelebil, Christopher J Lord, Alan Ashworth

Get full text

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency by Ilirjana Bajrami, Callum Walker, Dragomir B. Krastev, Daniel Weekes, Feifei Song, Andrew J. Wicks, John Alexander, Syed Haider, Rachel Brough, Stephen J. Pettitt, Andrew N. J. Tutt, Christopher J. Lord

Get full text

Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7 by Joseph S. Baxter, Rachel Brough, Dragomir B. Krastev, Feifei Song, Sandhya Sridhar, Aditi Gulati, John Alexander, Theodoros I. Roumeliotis, Zuza Kozik, Jyoti S. Choudhary, Syed Haider, Stephen J. Pettitt, Andrew N. J. Tutt, Christopher J. Lord

Get full text

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells by Anabel Zelceski, Paola Francica, Lea Lingg, Merve Mutlu, Colin Stok, Martin Liptay, John Alexander, Joseph S. Baxter, Rachel Brough, Aditi Gulati, Syed Haider, Maya Raghunandan, Feifei Song, Sandhya Sridhar, Josep V. Forment, Mark J. O’Connor, Barry R. Davies, Marcel A.T.M. van Vugt, Dragomir B. Krastev, Stephen J. Pettitt, Andrew N.J. Tutt, Sven Rottenberg, Christopher J. Lord

Get full text

Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes by Fresia Pareja, Rohit Bhargava, Virginia F. Borges, Edi Brogi, Rita Canas Marques, Fatima Cardoso, Christine Desmedt, Malini Harigopal, Sunil R. Lakhani, Adrian Lee, Jose Pablo Leone, Hannah Linden, Christopher J. Lord, Caterina Marchio, Sofia D. Merajver, Emad Rakha, Jorge S. Reis-Filho, Andrea Richardson, Elinor Sawyer, Pepper Schedin, Christopher J. Schwartz, Andrew Tutt, Naoto T. Ueno, Anne Vincent-Salomon, Britta Weigelt, Y. Hannah Wen, Stuart J. Schnitt, Steffi Oesterreich

Get full text